Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL146128 | 0.96 | — | — | |
| Acetic Acid SCHEMBL31228715 | 0.96 | FFAR3 (0.54) | — | |
| Acetic Acid SCHEMBL4970317 | 0.93 | — | — | |
| Acetic Acid SCHEMBL27592793 | 0.93 | — | — | |
| Acetic Acid SCHEMBL5066150 | 0.93 | — | — | |
| Acetic Acid SCHEMBL10644131 | 0.93 | FFAR3 (0.50) | — | |
| Acetone SCHEMBL2169438 | 0.89 | — | — | |
| Butyl Alcohol SCHEMBL11873328 | 0.88 | ALDH1A1 (0.61) | — | |
| Acetic Acid SCHEMBL27534278 | 0.87 | FFAR3 (0.44) | — | |
| Acetic Acid SCHEMBL21834420 | 0.87 | FFAR3 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440980-B2 | Remedy for diabetes | EA PHARMA CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20140309135-A1 | REMEDY FOR DIABETES | AJINOMOTO CO., INC. (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8772281-B2 | Remedy for diabetes | AJINOMOTO CO., INC. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130130277-A1 | REMEDY FOR DIABETES | AJINOMOTO CO., INC. (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8357680-B2 | Remedy for diabetes | AJINOMOTO CO., INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-20100093055-A1 | REMEDY FOR DIABETES | AJINOMOTO CO., INC. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2157092-A1 | REMEDY FOR DIABETES | Ajinomoto Co., Inc. (JP) | 2010-02-24 | — | — | EP | disclosed |
| EP-0309423-B1 | New benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-06-15 | — | — | EP | disclosed |
| EP-0309423-A2 | New benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1989-03-29 | — | — | EP | disclosed |
| US-4164447-A | TRANSFERS A CARBAMOYL GROUP TO 3-HYDROXYMETHYL CEPHALOSPORIN | GLAXO LABORATORIES LIMITED (GB) | 1979-08-14 | — | — | US | disclosed |